Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia

American Journal of Medicine

Volumn 123, Issue 8, 2010, Pages

  Wiggins, Charles L ^a,b   Harlan, Linda C ^c   Nelson, Harold E ^a   Stevens, Jennifer L ^d   Willman, Cheryl L ^b   Libby, Edward N ^b   Hromas, Robert A ^b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

Age discrimination; Chronic myeloid leukemia; Imatinib; Socioeconomic status

Indexed keywords

IMATINIB;

ADULT; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SOCIAL STATUS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LOGISTIC MODELS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PYRIMIDINES; SEER PROGRAM; SOCIAL CLASS; UNITED STATES;

EID: 77955496483     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.03.018     Document Type: Article

References (50)

1. M.S. Linet, S.S. Devesa, and G.J. Morgan The leukemias D. Schottenfeld, J.F. Fraumeni Jr Cancer Epidemiology and Prevention 2006 Oxford University Press 841 871
2. American Cancer Society Cancer Facts & Figures 2008 2008 American Cancer Society Atlanta, GA 4
3. M. Savona, and M. Talpaz Getting to the stem of chronic myeloid leukaemia Nat Rev Cancer 8 2008 341 350
4. M.W. Deininger, J.M. Goldman, and J.V. Melo The molecular biology of chronic myeloid leukemia Blood 96 2000 3343 3356
5. A.M. Carella, F. Frassoni, and J. Melo New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia Haematologica 82 1997 478 495
6. H.M. Kantarjian, F.J. Giles, and S. O'Brien Therapeutic choices in younger patients with chronic myelogenous leukemia Cancer 89 2000 1647 1658
7. B.J. Druker, S. Tamura, and E. Buchdunger Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells Nat Med 2 1996 561 566
8. M.W. Deiniger, J.M. Goldman, and N. Lydon The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells Blood 90 1997 3691 3698
9. B.J. Druker, M. Talpaz, and D.J. Resta Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
10. B.J. Druker, C.L. Sawyers, and H. Kantarjian Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 2001 1038 1042
11. H. Kantarjian, C. Sawyers, and A. Hochhaus Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 2002 645 652
12. B.J. Druker, F. Guilhot, and S.G. O'Brien Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
13. Food and Drug Administration, Center for Drug Evaluation and Research Approval Letter for Application Number NDA 21-335 May 10, 2001 http://www.fda.gov/cder/foi/nda/2001/21-335-Gleevec-Approv.pdf Accessed April 7, 2008
14. M.H. Cohen, J.R. Johnson, and R. Pazdur Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase Clin Cancer Res 9 2003 1972 1979
15. H. Brenner, A. Gondos, and D. Pulte Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level Haematologica 93 2008 1544 1549
16. L.C. Thygesen, O.J. Nielsen, and C. Johansen Trends in adult leukemia incidence and survival in Denmark, 1943-2003 Cancer Causes Control 20 2009 1671 1680
17. B.F. Hankey, L.A. Ries, and B.K. Edwards The Surveillance, Epidemiology, and End Results program: a national resource Cancer Epidemiol Biomarkers Prev 8 1999 1117 1121
18. N. Krieger, D.R. Williams, and N.E. Moss Measuring social class in US public health research: concepts, methodologies, and guidelines Annu Rev Public Health 18 1997 341 378
19. M.A. Butler, and C.L. Beale Rural-Urban Continuum Codes for Metro and Non-Metro Counties, 1993 Staff Report No. 9425 1994 Agriculture and Rural Economic Division, Economic Research Service, U.S. Department of Agriculture Washington, DC
20. R.C. Elandt-Johnson, and N.L. Johnson Survival Models and Data Analysis 1980 John Wiley & Sons, Inc New York
21. D.R. Cox, and D. Oaks Analysis of Survival Data 1984 Chapman and Hall London
22. Surveillance, Epidemiology, and End Results (SEER) Program SEER (*)Stat Database: Incidence - SEER 17 Registries Limited-Use + Hurricane Katrina Impacted Louisiana Cases, November 2007 Submission (1973-2005 varying); Linked to County Attributes - Total U.S., 1969-2005 Counties, National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch www.seer.cancer.gov Accessed April 7, 2008
23. Surveillance, Epidemiology, and End Results (SEER) Program SEER (*)Stat Database: Mortality - All Causes of Death, Aggregated with State, Total U.S. (1969-2004) National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2007 www.seer.cancer.gov Accessed April 7, 2008
24. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute Population estimates used in SEER (*)Stat software http://seer.cancer.gov/popdata/methods.html Accessed April 7, 2008
25. Surveillance Research Program SEER (*)Stat Software, Version 6.4.4 2008 National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch Bethesda, MD http://www.seer.cancer.gov/seerstat Accessed March 3, 2009
26. H.J. Kim, M.P. Fay, E.J. Feuer, and D.N. Midthune Permutation tests for Joinpoint regression with applications to cancer rates Stat Med 19 2000 335 351
27. Joinpoint Regression Program, Version 3.2.0 2008 Statistical Research and Applications Branch, National Cancer Institute Bethesda, MD
28. J. Cortes, M. Talpaz, and S. O'Brien Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia Cancer 98 2003 1105 1113 (Pubitemid 37099894)
29. D. Crivellari, M. Bonetti, and M. Castiglione-Gertsch Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII J Clin Oncol 18 2000 1412 1422
30. I. Carreca, L. Balducci, and M. Extermann Cancer in the older person Cancer Treat Rev 31 2005 380 402
31. C. Bouchardy, E. Rapiti, and S. Blagojevic Older female cancer patients: importance, causes, and consequences of undertreatment J Clin Oncol 25 2007 1858 1869
32. R.A. Silliman, E. Guadagnoli, and A.B. Weitberg Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients J Gerontol 44 1989 M46 M50
33. H. Chen, A. Cantor, and J. Meyer Can older cancer patients tolerate chemotherapy? A prospective pilot study Cancer 97 2003 1107 1114
34. L. Repetto, and L. Balducci A case for geriatric oncology Lancet Oncol 3 2002 289 297
35. L.F. Hutchins, J.M. Unger, and J.J. Crowley Under-representation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 1999 2061 2067
36. K.W. Yee, and A. Keating Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 21 2003 1618 1623
37. G.G. Kimmick, B.L. Peterson, and A.B. Kornblith Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001 J Clin Oncol 23 2005 2201 2207
38. C.A. Townsley, R. Selby, and L.L. Siu Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials J Clin Oncol 23 2005 3112 3124
39. N. Kearney, M. Miller, and J. Paul Oncology healthcare professionals' attitudes toward elderly people Ann Oncol 11 2000 599 601
40. I.S. Fentiman, U. Tirelli, and S. Monfardini Cancer in the elderly: why so badly treated? Lancet 335 1990 1020 1022
41. R.C. Maly, B. Leake, and R.A. Silliman Breast cancer treatment in older women: impact of the patient-physician interaction J Am Geriatr Soc 52 2004 1138 1145 (Pubitemid 38869073)
42. D.H. Moore, J.T. Kauderer, and J. Bell An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study Gynecol Oncol 94 2004 368 374
43. C.A. Townsley, K.K. Chan, and G.R. Pond Understanding the attitudes of the elderly towards enrolment into cancer clinical trials BMC Cancer 6 2006 34
44. F. Keime-Guibert, O. Chinot, L. Taillandier Association of French-Speaking Neuro-Oncologists Radiotherapy for glioblastoma in the elderly N Engl J Med 356 2007 1527 1535
45. Food and Drug Administration: November 1989 Guideline for the Study of Drugs Likely to Be Used in the Elderly Fed Register 59 1994 39398 39400
46. L. Balducci, H.J. Cohen, and P.F. Engstrom Senior adult oncology clinical practice guidelines in oncology J Natl Comp Canc Netw 3 2005 572 590
47. R.W. Carlson, S. Moench, and A. Hurria NCCN Task Force Report: breast cancer in the older woman J Natl Comp Canc Netw 6 Suppl 4 2008 S1 S25
48. L. Repetto, L. Fratino, and R.A. Audisio Comprehensive geriatric assessment adds information to Eastern Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study J Clin Oncol 20 2002 494 502
49. S. Epstein The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials Sci Technol Human Values 20 1995 408 437
50. B. Lerner Breast cancer activism: past lessons, future directions Nat Rev Cancer 2 2002 225 230